Technology
AmorphOX is powering tomorrow’s treatments
AmorphOX® is a powder-based drug delivery technology that stabilizes amorphous materials - such as peptides and biologics - and is designed to support strong bioavailability, enabling next-generation drug development.
AmorphOX in numbers
0
Years of experience with next-generation drug delivey technolgy AmorphOX®
0
AmorphOX-based formulations under research
0
Clinical trials with AmorphOX® technology
0
Patents granted and submitted
The challenge
Amorphous materials are increasingly central to modern drug development, where they play a vital role in how treatments perform. Unlike crystalline substances, amorphous materials lack long-range molecular order, giving them unique and highly valuable properties, most notably, exceptionally rapid dissolution in aqueous environments. Historically, amorphous drug formulations have faced challenges with chemical and physical stability during storage, limiting their use: AmorphOX overcomes these limitations.
Amorphous materials
Crystalline materials
The solution
AmorphOX is a monoparticulate powder that integrates an active pharmaceutical ingredient (API), carrier materials and, when needed, additional excipients. Developed over eight years of dedicated research, AmorphOX is manufactured using a sophisticated spray-drying process. The powder can be tailored for specific requirements, including particle size, dissolution characteristics and mucosal retention.
Key attributes
Versatile applications
Adaptable across multiple therapeutic areas and formulations.
Ultra-fast absorption
Designed for rapid onset, improving treatment efficiency.
Superior bioavailability
Maximizes active ingredient performance for optimal outcomes.
Chemical and physical stability
Protects sensitive molecules, ensuring integrity and efficacy.
Needle-free delivery
Enhances patient comfort and compliance with non-invasive options.
Preservative-free formulation
Clean, safe, and aligned with modern health standards. Reduces complexity and risk of microbial contamination compared to liquid sprays.
Stabilizing sensitive molecules to enable easier handling, transport and storage
Through extensive testing - including 21 APIs, over 500 formulations, and five clinical studies -AmorphOX has demonstrated its ability to stabilize a wide range of molecules. This enables simpler manufacturing, storage, and distribution, without reliance on cold-chain systems.
By removing cold-chain constraints, AmorphOX has the potential to expand access to medicines in regions with limited infrastructure, while supporting new delivery opportunities for vaccines and emergency treatments.
Manufactured by spray-drying
3 questions to Orexo’s SVP and Head of R&D, Robert Rönn
What does formulating powder-based products involve?
We formulate active pharmaceutical ingredients together with certain excipients, using a spray drying process, into fine, dry particles suitable for advanced delivery routes like intranasal or inhalation. AmorphOX®, our monoparticulate platform, offers exceptional stability and high bioavailability.
What are the advantages?
Powder formulations extend shelf life, increase speed of onset and improve bioavailability. Their thermal stability properties allow for more flexible handling and storage, and remove cold-chain requirements, simplifying global distribution.
What makes AmorphOX® innovative?
It enables fast-acting, stable formulations with high bioavailability for a wide range of molecules, including peptides and biologics traditionally dependent on cold storage.
